Clinical Trial ProgressProtara's TARA-002 has shown a similar efficacy and slightly better safety profile compared to BCG in the Phase 2 ADVANCED-2 trial in BCG-Naive NMIBC patients.
Market OpportunityWith three major catalysts in the next 12 months, an undervalued pipeline asset with a large market opportunity, as well as negative news for competitors presenting clear openings for Protara, the analyst is initiating on TARA with a BUY rating and $21 PT.
Regulatory AlignmentProtara recently received alignment with the FDA on the registration trial for IV Choline in Parenteral Support patients, indicating progress in its clinical pipeline.